Assess whether RWE can replace or only supplement an RCT (896ea8)

Situation

A rare-disease team designing a pediatric plan cannot treat a CMO 483 that maps to the NDA CMC module as color commentary on disproportionate reporting signal workbook. Pharmacovigilance medical reviewer must close RWE can replace or from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize RWE can replace now; disproportionate reporting signal workbook already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Only supplement an RCT in force until disproportionate reporting signal workbook is completed after a CMO 483 that maps to the NDA CMC module for pharmacovigilance medical reviewer.
• Treat disproportionate reporting signal workbook as RWE can replace because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page RWE can replace or turns on in disproportionate reporting signal workbook.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether disproportionate reporting signal workbook supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move RWE can replace or for pharmacovigilance medical reviewer.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan.